4/A: Enliven CEO Sells 1,517 Shares Under 10b5-1 Plan

Enliven Therapeutics' President and CEO, Samuel Kintz, reported the sale of 1,517 common shares for approximately $20.00 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Samuel Kintz, President and CEO, and a Director of Enliven Therapeutics, Inc. (ELVN), filed an amended Form 4 (Form 4/A).
• The amendment corrects an omission from the original Form 4 filed on August 20, 2025, to report a sale of common stock.
• Kintz disposed of 1,517 shares of Enliven Therapeutics common stock on August 20, 2025.
• The shares were sold at a weighted average price of $20.0023 per share, with individual trades ranging from $20.00 to $20.03.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Kintz on November 15, 2024.
• Following this transaction, Kintz beneficially owns 927,892 shares, which are held indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing. While an insider sale can sometimes be viewed negatively, the fact it was under a 10b5-1 plan mitigates concerns. The amendment is a correction, not new negative news.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new, potentially negative, information.
• The company demonstrated transparency by filing an amendment to accurately reflect insider transactions, correcting an initial oversight.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake.
• The necessity of filing an amendment suggests an initial oversight in reporting the transaction.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or the competitive landscape. Insider sales under 10b5-1 plans are common across industries for executives managing their personal portfolios.

Comparison to Industry Standards

• This filing is a routine disclosure of an insider stock sale under a 10b5-1 plan, which is a standard practice for executives to manage their equity holdings while avoiding accusations of trading on material non-public information. There are no specific company or project results to compare against industry benchmarks in this filing.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the CEO's direct equity stake, which is generally a neutral event given it was pre-planned under a 10b5-1 plan. The transparency of the amendment is positive.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person, beyond the completion of this transaction.

Key Dates

Recommendation

This Form 4/A filing reports a routine, pre-scheduled insider stock sale by the CEO under a 10b5-1 plan. Such transactions are common for executives managing personal finances and typically do not reflect a change in the company's fundamental outlook or performance. The number of shares sold is a small fraction of the CEO's total beneficial ownership. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is maintained pending further material developments.

Keywords

Enliven Therapeutics, ELVN, Samuel Kintz, Insider Trading, Form 4/A, Stock Sale, 10b5-1 Plan, CEO, Director